Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: A pilot study

Digestive and Liver Disease

Volumn 36, Issue 4, 2004, Pages 278-285

  Mazzanti, R ^a   Giallombardo, A L ^a   Mini, E ^b   Nobili, S ^b   Neri, B ^a   Arena, U ^a   Pantaleo, P ^a   Fabbroni, V ^a   Ghilardi, M ^a   Gattai, R ^b   Bandettini, L ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Hepatocarcinoma; Intra arterial chemotherapy; Kizzlosis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTERY CATHETER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHOLESTATIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; OUTCOMES RESEARCH; PILOT STUDY; PORTAL VEIN THROMBOSIS; SURVIVAL TIME; CLINICAL TRIAL; INTRAARTERIAL DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUOROURACIL; HUMANS; INJECTIONS, INTRA-ARTERIAL; LEUCOVORIN; MALE; MIDDLE AGED; PILOT PROJECTS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 3543143016     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2003.12.013     Document Type: Article

References (39)

1. Di Bisceglie AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13:S169-71.
2. Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol 2002;17:401-5.
3. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122:1609-19.
4. Romeo R, Colombo M. The natural history of hepatocellular carcinoma. Toxicology 2002;182:39-42.
5. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 2003;238:508-18.
6. Bolondi L, Piscaglia F, Camaggi V, Grazi GL, Cavallari A. Review article: liver transplantation for HCC. Treatment options on the waiting list. Aliment Pharmacol Ther 2003;17 (suppl. 2):145-50.
7. Livraghi T. Radiofrequency ablation, PEIT, and TACE for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2003;10:67-76.
8. Barnett Jr CC, Curley SA. Ablative techniques for hepatocellular carcinoma. Semin Oncol 2001;28:487-96.
9. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27:1578-83.
10. Bruix J, Castells A, Montanya X, Calvet X, Bru C, Ayuso C, et al. Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology 1994;20:643-50.
11. Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181-4.
12. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995;332:1256-61.
13. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumour progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003;9:557-63.
14. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
15. Yuen MF, Chan AO, Wong BC, Hui CK, Ooi GC, Tso WK, et al. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol 2003;98:1181-5.
16. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Tung-Ping Poon R, et al. Chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71.
17. Yu AS, Keeffe EB. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003;3:8-24.
18. Johnson PJ. Are there indications for chemotherapy in hepatocellular carcinoma? Surg Oncol Clin N Am 2003;12:127-34.
19. Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B. Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol 2002;35:S109-14.
20. Chao Y, Chan WK, Wang SS, Lai KH, Chi CW, Lin CY, et al. Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:277-81.
21. Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002;36:687-91.
22. Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 2002;29:119-25.
23. Bilchik AJ. Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: an update. Surg Oncol Clin N Am 2003;12:193-210.
24. Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003;23:1891-7.
25. Murata K, Shiraki K, Kawakita T, Yamamoto N, Okano H, Nakamura M, et al. Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 2003;23:1719-22.
26. Itamoto T, Nakahara H, Tashiro H, Haruta N, Asahara T, Naito A, et al. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumour thrombus of the portal vein. J Surg Oncol 2002;80: 143-8.
27. Leung TW, Johnson PJ. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001;28:514-20.
28. Milano G, Chamorey AL. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int 2002;19:177-89.
29. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989;58:137-71.
30. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
31. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-5.
32. The Cancer of the Liver Italian Program (CLIP) investigation. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31:840-5.
33. Group de'etude et de Traitement du Carcinoma Hepatocellulair. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999;31:133-41.
34. Llovet JM, Bru C, Broux J. Prognosis of hepatocellular carcinoma: The Barcelona Clinic Liver Cancer Staging Classification. Semin Liver Dis 1999;3:329-37.
35. Del Campo C. Simplified insertion of the Port-A-Cath implantable drug-delivery system. Can J Surg 1985;28:435-6.
36. Green S, Weiss GR. Southwest Oncology Group standard response criteria. Invest New Drugs 1992;10:239-53.
37. Ebied OM, Federle MP, Carr BI, Pealer KM, Li W, Amesur N, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2003;97:1042-50.
38. Jia WD, Xu GL, Xu RN, Sun HC, Wang L, Yu JH, et al. Octreotide acts as an antitumor angiogenesis compound and suppresses tumour growth in nude mice bearing human hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol 2003;129:327-34.
39. Suzuki K, Ohkoshi S, Yano M, Ichida T, Takimoto M, Naitoh A, et al. Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis. Liver Int 2003;23:143-7.